Drug Delivery Systems

Drug Delivery Systems

Inhaled drug delivery systems face unique stability challenges that need to be managed in order to meet label claim dosages and improve patient compliance. From keeping powder formulations dry within a delivery system, to controlling the build-up of powder in the delivery channel, to maintaining the integrity of APIs within capsule- and reservoir-based DPIs (dry powder inhalers) and pMDIs (pressurized metered-dose inhalers), Aptar CSP Technologies can custom-design a solution to meet your drug product’s stability needs so you can deliver an optimal patient and consumer experience.

Aptar CSP’s proprietary 3-Phase Activ-Polymer™ platform technology can be integrated into virtually any inhaled drug product to adsorb moisture, oxygen or volatile organic compounds, mitigating failure of product integrity and/or stability.

Solutions for inhaled drug devices can be designed in a variety of configurations including:

• Active Molded Components that serve as an integral part of the inhaled drug delivery device
• Secondary Packaging Solutions
• Activ-Blister™ Solutions to protect individual blister cavities enclosing capsules for capsule-based DPIs

3-Phase Activ-Polymer™ Components

Active molded components can be seamlessly integrated into an inhaled drug delivery device (DPI and pMDIs) by replacing a current plastic part in the device, providing the part’s physical functioning while incorporating the material science performance. As an example, pMDIs face chronic challenges with post-actuation particle build-up at the stem valve, spray nozzle, and mouthpiece of the actuator. Using an integrated active molded component around the canister or within the actuator can prevent these often ignored limitations that cause sub-therapeutic treatment. DPIs offer a different challenge, whereby keeping the powder formulation protected from the outside environment, from bulk formulation, to blister filling, to finished product manufacturing, is critical to maintaining dose integrity. Integrating an active molded component inside a device, particularly reservoir-based DPIs, ensures a drier environment for the device’s delivery pathway, reducing build up and ensuring better dosage delivery for patients.